Ropes & Gray represented Coherus BioSciences in the transaction.
Coherus BioSciences, Inc. entered into a $1.1 billion immune-oncology collaboration agreement with Junshi Biosciences directed towards the development and commercialization of Junshi’s programmed cell death protein (anti-PD-1) monoclonal antibody, toripalimab, in the United States and Canada. Under the terms of the agreement, Coherus received a license for toripalimab, two option programs, and first negotiation rights to two early-stage checkpoint inhibitor antibodies.
Founded in December 2012, Junshi Biosciences (HK: 1877; SH: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics.
Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system.
The Ropes & Gray team advising Coherus BioScience was led by life sciences licensing and collaborations partner Hannah Freeman (Boston; Picture) and IP transactions associate Jimmy Chen (San Francisco) and included capital markets partner Zachary Blume, IP transactions partner David McIntosh (both of Boston), and litigation & enforcement partner Ama Adams (Washington, D.C.).
Law Firms: Ropes & Gray;
Clients: Coherus Biosciences Inc;